Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
38.33 USD | +0.50% | +1.00% | +33.65% |
May. 09 | Wedbush Raises Price Target on Revolution Medicines to $46 From $42, Maintains Outperform Rating | MT |
May. 08 | Revolution Medicines Q1 Net Loss Narrows | MT |
Business Summary
Number of employees: 411
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Novel Targeted Therapies
100.0
%
| 35 | 100.0 % | 12 | 100.0 % | -67.27% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 35 | 100.0 % | 12 | 100.0 % | -67.27% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Mark Goldsmith
CEO | Chief Executive Officer | 62 | 14-09-30 |
Jack Anders
DFI | Director of Finance/CFO | 47 | 18-07-31 |
Wally Reiher
CTO | Chief Tech/Sci/R&D Officer | - | 15-07-31 |
Wei Lin
CTO | Chief Tech/Sci/R&D Officer | 63 | 23-03-31 |
Steve Kelsey
CTO | Chief Tech/Sci/R&D Officer | 63 | 17-02-28 |
Peg Horn
COO | Chief Operating Officer | 61 | - |
Linnet Zia
PRN | Corporate Officer/Principal | - | 19-02-28 |
Jeff Cislini
LAW | General Counsel | 49 | 19-12-31 |
Daniel Simon
PRN | Corporate Officer/Principal | - | 22-08-31 |
Xiao Lin Wang
PRN | Corporate Officer/Principal | 53 | 18-02-28 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Mark Goldsmith
CEO | Chief Executive Officer | 62 | 14-09-30 |
Alexis Borisy
BRD | Director/Board Member | 52 | 14-10-31 |
Sandra Horning
BRD | Director/Board Member | 75 | Nov. 08 |
Barbara Weber
BRD | Director/Board Member | 67 | 18-03-31 |
Thilo Schroeder
BRD | Director/Board Member | 42 | 18-02-28 |
Lorence Kim
BRD | Director/Board Member | 49 | 22-07-11 |
Director/Board Member | 66 | 15-02-28 | |
Flavia Borellini
BRD | Director/Board Member | 64 | 21-06-21 |
Sushil Patel
BRD | Director/Board Member | 52 | 22-06-15 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 170,546,280 | 160,457,305 ( 94.08 %) | 5,560,053 ( 3.260 %) | 94.08 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+33.65% | 6.32B | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B | |
-11.83% | 10.74B |
- Stock Market
- Equities
- RVMD Stock
- Company Revolution Medicines, Inc.